Despite the fact that a significant number of tumors expressed PD-L1 in GBM [32], the pre-clinical evidence supporting the anti-tumor activity of anti-PD-1/PD-L1 has been limited to one orthotopic syngeneic glioma model [33–35]. The gene discussed is CD274; the disease is neoplasm.